



Molecular Mechanisms and Novel Therapies for Brain Injury

Guest Editor:

Dr. Arjun Sapkota

Neuroscience Lab, San Diego
Biomedical Research Institute,
San Diego, CA 92121, USA

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Dear Colleagues,

Brain injury—whether that be stroke, spinal cord injury, traumatic brain injury, seizure, brain tumors—is the leading cause of death and disability globally. To date, numerous efforts have been made to develop new therapeutics that modulate the pathogenesis of brain injury. Unfortunately, these studies have not led to the successful development and discovery of new drug targets, biomarkers, and therapeutics that tackle brain injury. Therefore, uncovering the molecular mechanisms of injury, recovery, and neuroprotection is important for the development of novel, effective therapies.

This Special Issue aims to collect up-to-date overviews of the current understandings of brain injury, molecular mechanisms, and novel therapies, as well as the possible clinical translations and therapeutic strategies to treat brain injury. These should highlight, but are not limited to, molecular or genetic manipulation affecting protective or detrimental outcomes, the mechanisms of action of various pharmacological agents, innovative therapeutic strategies for treatment, and neuroinflammation.

Dr. Arjun Sapkota
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)